Compare Intercontinental Exchange Inc. Common Stock (ICE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intercontinental Exchange Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Intercontinental Exchange Inc. Common Stock trades at $156.7 (market cap $87.08B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Intercontinental Exchange Inc. Common Stock is far larger — about 11.8× Spyre Therapeutics Inc. Common Stock's market cap, and Intercontinental Exchange Inc. Common Stock pays a 1.34% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| ICE | SYRE | |
|---|---|---|
Market Cap | $87.08B | $7.35B |
Volume | 3,543,870 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $175.10 | $108.92 |
52-Week Low | $122.91 | $22.18 |
Enterprise Value | $104.98B | $6.35B |
Dividend Yield | 1.34% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intercontinental Exchange (ICE) trades at $156.42, down 0.64% on the day, with strong technical momentum showing bullish moving averages and key support at $155. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $1.90 versus $1.84, maintaining a three-quarter beat streak. Revenue growth accelerated to $13.4 billion in 2026 with net profit margin expanding to 30.07%, supported by record trading volumes in key markets.
ICE presents a compelling investment case with 89% analyst buy ratings and a $183.89 consensus price target implying 17.6% upside. The exchange operator's diversified platform and recurring revenue model provide stability, though investors should monitor competitive pressures and market volatility impacts. Strong cash flow generation and institutional support reinforce the bullish outlook despite near-term technical overbought conditions.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Intercontinental Exchange Inc. Common Stock
Intercontinental Exchange provides technology and data services for financial institutions, corporations, and governments. Its businesses include exchanges and clearing, fixed-income data and analytics, and mortgage technology.
Read more on ICE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
